Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (10330)	6/3/1999 2:21:00 PM
From: aknahow	Respond to of 17367

79/260 + 30% And as you state and I have said this would be low because of the forced distribution of one half of the 34 trial deaths into the treatment arm. Remember that if BPI gave the same results as the the placebo we would not be having this discussion. If worse, XOMA could market the placebo. Bottom line we have a lot of evidence that the disease kills even those in hospitals and that for whatever reason those in the trial died at a much lower rate, than indicated by many other references or than the 62 deaths themselves indicate.